Copy of Professor Jing Pan: Breakthroughs and Prospects of Performance-Enhanced CD33 CAR-T Cells in the Treatment of Relapsed or Refractory AML
In the field of hematologic oncology, treating acute myeloid leukemia (AML) has always been challenging, especially for relapsed or refractory patients. The limitations of traditional chemotherapy underscore the urgent need for innovative treatments. With advancements in immunotherapy, CAR-T cell therapy has introduced new breakthroughs in AML treatment. The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, USA. The "Phase I Study of Performance-Enhanced CD33 CAR-T Cells in Relapsed or Refractory AML Patients" was presented as a poster, aiming to explore the safety and preliminary efficacy of a novel CAR-T cell therapy in this patient group. "Oncology Frontier - Hematology Frontier " invited the study’s first author, Director Jing Pan from Beijing GoBroad Boren Hospital, to provide an in-depth interpretation of the research and share insights into advancements in AML diagnosis and treatment.